Shandong Buchang Pharmaceuticals Co., Ltd. (SHA:603858)
China
· Delayed Price · Currency is CNY 16.59
-0.13 (-0.78%)
At close: Mar 9, 2026
SHA:603858 Revenue
Shandong Buchang Pharmaceuticals had revenue of 2.80B CNY in the quarter ending September 30, 2025, a decrease of -9.02%. This brings the company's revenue in the last twelve months to 10.96B, down -6.93% year-over-year. In the year 2024, Shandong Buchang Pharmaceuticals had annual revenue of 11.01B, down -16.91%.
Revenue (ttm)
10.96B
Revenue Growth
-6.93%
P/S Ratio
1.60
Revenue / Employee
1.43M
Employees
7,689
Market Cap
17.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.01B | -2.24B | -16.91% |
| Dec 31, 2023 | 13.25B | -1.71B | -11.41% |
| Dec 31, 2022 | 14.95B | -811.43M | -5.15% |
| Dec 31, 2021 | 15.76B | -244.03M | -1.52% |
| Dec 31, 2020 | 16.01B | 1.75B | 12.28% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Jan 1, 2018 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tonghua Dongbao Pharmaceutical | 2.74B |
| Zhejiang Medicine | 8.96B |
| Fujian Cosunter Pharmaceutical | 430.98M |
| Betta Pharmaceuticals | 3.26B |
| Walvax Biotechnology | 2.40B |
| China Resources Double-Crane Pharmaceutical | 10.95B |
| Shenzhen Kangtai Biological Products | 2.70B |
| Nanjing King-Friend Biochemical Pharmaceutical | 3.76B |